National Healthcare

What National Healthcare does

National Healthcare Pvt. Ltd. is a Nepalese pharmaceutical manufacturer founded on April 10, 1996 and headquartered in Birgunj, Nepal. The company manufactures and markets 200+ finished dosage pharmaceutical products across 14 therapeutic categories — including antithrombotics, antidiabetics, antimicrobials, cardiovascular drugs, dermatologicals, gastrointestinals, musculoskeletal drugs, nervous system drugs, nutritional supplements, ophthalmic/otic products, renal drugs, respiratory drugs, and antifibrinolytics. It distributes these products through 10+ specialized marketing divisions (National, Status, Spectra-Azul, Spectra-Rojo, Otiva, Optima, Maxima National, Maxima Eyecare, Lumina, Delica, Chroma) that target hospitals, clinics, pharmacies, and medical practitioners across Nepal.

The company's manufacturing footprint consists of five dedicated production blocks at its Bara production facility: a General Block, a Cephalosporin Block (tablets and dry powder for injection), a Penicillin Block (tablets, capsules, oral dry syrup, dry powder for injection), a Sterile Block (small volume parenterals, ophthalmic products, and lyophilized products), and a newly commercialized Solid Dosage Form Block (dry powder inhalers). National Healthcare self-identifies as a pioneer in dry powder for injection, small volume parenteral, and lyophilized manufacturing in Nepal; key technical milestones include the establishment of the Sterile Plant (2005), the Lyophilized Plant (2016), and the launch of Vanesco-500, Nepal's first lyophilized injectable product, in 2017. Recent launches include Rocumide (2025), Sacuval (2024), and Rofumil (2023).

National Healthcare generates revenue through the direct manufacturing and sale of pharmaceutical products via its own field sales force operating through its 10+ marketing divisions, selling to healthcare providers and pharmacies within Nepal. Pricing is not publicly disclosed and operates on a quote-based medical channel model. The company is privately held, incorporated in Nepal, and operates exclusively in the domestic market with no disclosed international footprint, no subsidiaries, and no external institutional investors. In March 2025, the company launched the 'Mano Yatra' digital platform on Facebook and Instagram as its first consumer-facing digital initiative focused on mental well-being.

Name

National Healthcare

Legal name

National Healthcare Pvt. Ltd.

Website

https://nationalhealthcare.com.np

Company type

Private

Founded year

1996

Operating status

Operating

Headcount range

501–1,000 employees

Short description

National Healthcare Pvt. Ltd. is a Nepalese pharmaceutical manufacturer founded in 1996 that produces and markets 200+ branded generic drugs across 14 therapeutic categories through 10+ marketing divisions, serving hospitals, pharmacies, and medical practitioners across Nepal from five dedicated production blocks.

Ownership category

akta.pro rank

Product category

Pharmaceutical Manufacturing

NAICS

Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (32541)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Primary Care & General Medicine Pharmaceuticals (HLAIAAAA)

akta.pro secondary industries

Pulmonology & Allergy Specialty Pharmaceuticals (HLAIACAF), Generic Hospital & Institutional Products (HLAIABAL)

Keywords

• Pharmaceutical manufacturing
• Lyophilized injectables
• Dry powder injections
• Generic medicines
• Cephalosporin antibiotics

Headquarters

HQ city

Birganj

HQ country

Nepal

HQ region

Asia

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations, Personnel, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Pharmaceutical Product Sales: Manufacturing and marketing of pharmaceutical products across 14 therapeutic categories including antidiabetics, cardiovascular drugs, antimicrobials, respiratory drugs, ophthalmic products, and more. Products are sold through 10+ marketing divisions in the Nepalese market.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

National Healthcare is a Nepal-based pharmaceutical manufacturer that produces and markets 200+ drug products spanning 14 therapeutic categories, including dry powder for injection, small volume parenteral, lyophilized injectables, oral solids (tablets, capsules), oral liquids, ophthalmic/otic drops, and dry syrups. Manufacturing is carried out across five dedicated blocks (General, Cephalosporin, Penicillin, Sterile, and Solid Dosage Form), and products are distributed through 10+ branded marketing divisions covering the Nepalese market.

Product overview

National Healthcare is a Nepalese pharmaceutical company offering 200+ products across 10+ marketing divisions. The product portfolio spans 14 therapeutic categories including Antithrombotics, Antidiabetics, Antihistamines, Antimicrobials, Cardiovascular Drugs, Dermatological Products, Gastrointestinal Drugs, Musculoskeletal Drugs, Nervous System Drugs, Nutritional Supplements, Ophthalmic/Otic Products, Renal Drugs, Respiratory Drugs, and Antifibrinolytics. The company operates through specialized marketing divisions: National (general products), Status (dermatology/pain), Spectra-Azul (cardiovascular/diabetes), Spectra-Rojo (cardiovascular/antidiabetics), Otiva (hospital injectables), Optima (nutritional/respiratory), Maxima National (general), Maxima Eyecare (ophthalmics), Lumina (dermatology/nutrition), Delica (neurological), and Chroma (pain/anti-infectives). Manufacturing is conducted across five specialized blocks: General Block, Cephalosporin Block, Penicillin Block, Sterile Block (Small Volume Parenteral, Ophthalmic, Lyophilized), and Solid Dosage Form Block.

Differentiator

Problem solved

Functional benefit

Brands

• National: Marketing division offering pharmaceutical products including antibiotics, cardiovascular drugs, and various therapeutic medications.
• Status
• Spectra - Azul
• Spectra - Rojo
• Otiva
• Optima
• Maxima National
• Maxima Eyecare
• Lumina National
• Delica National
• Chroma National

Products and services

• Rocumide (Rocuronium Bromide 10 mg/ml Injection) Neuromuscular blocking agent injection in 5 ml vial for adjunct to general anesthesia to facilitate rapid sequence and routine tracheal intubation and skeletal muscle relaxation during surgery or mechanical ventilation; for hospital and anesthesia use.
• Sacuval (Sacubitril + Valsartan) Combination therapy for heart failure management; first product commercialized from the newly built Solid Dosage Form Block in 2024.
• Rofumil (Roflumilast) Phosphodiesterase-4 inhibitor indicated for respiratory conditions such as severe COPD.
• Lipofol (Propofol 10 mg/ml Emulsion) Propofol 10 mg/ml emulsion in 20 ml vial for induction and maintenance of general anesthesia in adults and children over 1 month.
• Levetor (Levetiracetam 100 mg/ml Injection) Antiepileptic medication available in 100 mg/ml injection, 100 mg/ml oral solution, 250 mg tablet, and 500 mg/750 mg extended-release tablets for neuro use.
• Ticalor (Ticagrelor Tablets 60 mg & 90 mg) Antiplatelet medication (Ticagrelor) available in 60 mg and 90 mg tablet strengths for cardiovascular/antithrombotic use.
• Remsivir (Remdesivir Injection) Antiviral injection (Remdesivir) for treatment of severe viral infections; supplied as a sterile injectable.
• Rheuza-6 / Rheuza-12 (Benzathine Penicillin DPI) Benzathine Penicillin dry powder for injection in 600,000 and 1,200,000 unit strengths; antibiotic for rheumatic fever and syphilis treatment.
• Dabirom (Dabigatran Etexilate Capsules) Direct oral anticoagulant (Dabigatran) available in 75 mg and 110 mg capsules for anticoagulation therapy.
• Vanesco-500 (Vancomycin 500 mg Lyophilized Injection) Lyophilized Vancomycin 500 mg injection — first lyophilized product manufactured in Nepal; for treatment of severe bacterial infections including MRSA.
• Tazolin 2.25 & 4.5 (Piperacillin + Tazobactam DPI) Broad-spectrum intravenous antibiotic combination of Piperacillin 2 g/4 g + Tazobactam 250 mg/500 mg for treating severe bacterial infections including pneumonia, skin, gynecological, and abdominal infections.
• Super-CV Line (Amoxicillin + Clavulanic Acid) Beta-lactam antibiotic combination available in 375 mg, 625 mg, and 1000 mg tablets, 30 ml dry syrup, and 1.2 g dry powder for injection.
• Stacef DPI (Ceftriaxone Dry Powder for Injection) Third-generation cephalosporin antibiotic (Ceftriaxone) dry powder for injection available in 250 mg, 500 mg, 1 g, and 2 g vials; pioneer Cephalosporin DPI product.
• Camlo (Amlodipine Besylate Tablets) Calcium channel blocker antihypertensive (Amlodipine Besylate) available in 2.5 mg, 5 mg, and 10 mg tablet formulations; first cardiac product of the company.
• Netformin (Metformin HCl Tablets) Biguanide antidiabetic (Metformin HCl) tablets in 500 mg, 850 mg, 1000 mg, and various SR/ER formulations for Type 2 diabetes management.
• Moist Duo Lubricating Eye Drops Carboxymethylcellulose Sodium 0.5% w/v + Glycerin 0.9% w/v lubricating eye drops for extra hydration in mild to moderate dry eye conditions.
• Moist Trio Lubricating Eye Drops
• Tussive Dx Cough Syrup
• HIST (Fexofenadine) Antiallergic
• Brica-BM Cough Syrup
• Relixa (Apixaban Tablets)
• Dacrozin (Dapagliflozin Tablets)
• Neurega (Pregabalin) Capsules
• Camlo-L (Amlodipine + Losartan) Tablets
• Miox (Moxifloxacin) Eye Drops
• Azithro (Azithromycin)
• HYBRO SVP (Hyoscine Butylbromide 1 ml Injection) Small volume parenteral (Hyoscine Butylbromide 1 ml injection) for gastrointestinal spasm relief.

Quantifiable outcome

• First Lyophilized product launched in Nepal
• +1 more outcomes

Segments3 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Scale indicators4 records

Recent moves8 records

Expansion highlights4 records

Broad incumbents

• Sun Pharmaceutical Industries: India-headquartered global generic and specialty pharmaceutical manufacturer with a broad portfolio spanning multiple therapeutic categories. Comparable as a large-scale low-cost generic producer whose products compete directly with National Healthcare's branded generics in the Nepalese market.
• Cipla Limited: One of India's largest pharmaceutical companies with extensive operations across therapeutic areas including respiratory, cardiology, and anti-infectives — therapeutic categories that overlap heavily with National Healthcare's portfolio. Comparable as a broader incumbent whose products are widely distributed in Nepal and compete for the same prescriptions.
• Dr. Reddy's Laboratories: Major Indian multinational pharmaceutical company with a portfolio covering generics, APIs, and biosimilars across therapeutic categories that overlap with National Healthcare's. Comparable as a broad incumbent whose formulations are widely distributed across South Asia, including Nepal.

Direct peers

• Nepal Pharmaceuticals Lab: One of the oldest Nepalese pharmaceutical manufacturers producing tablets, capsules, liquids, and injectables for the domestic market. Comparable as a domestic Nepalese pharma peer with overlapping therapeutic categories and similar manufacturing/sales model.
• Time Pharmaceuticals: Nepal-based pharmaceutical manufacturer with a broad portfolio of branded generics across therapeutic categories including cardiovascular, anti-infectives, and respiratory. Directly comparable as a domestic Nepalese pharma with similar manufacturing and marketing footprint.
• Alpine Pharmaceuticals: Nepal-based pharmaceutical manufacturer producing generic formulations across multiple therapeutic categories for the domestic market. Comparable as a Nepalese pharma peer serving the same healthcare provider and pharmacy channels.
• Deurali-Jantar Pharmaceutical: One of Nepal's largest domestic pharmaceutical manufacturers producing tablets, capsules, injectables, and ointments across multiple therapeutic categories. Closely comparable as a Nepal-headquartered, multi-division pharma manufacturer serving the same hospital and pharmacy channels as National Healthcare.

Regional players

• Royal Pharmaceuticals: Nepal-based pharmaceutical company manufacturing oral solids, injectables, and topical formulations for the domestic market. Comparable as a regional player operating in the same Nepalese market with similar therapeutic breadth and distribution approach.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

• Facebookfacebook.com/profile.php
• LinkedInlinkedin.com/company/national-healthcare-pvt-ltd

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about National Healthcare